Logo

CHARM Therapeutics Collaborated with BMS to Advance Small Molecule Drug Discovery Programs

Share this
CHARM Therapeutics

CHARM Therapeutics Collaborated with BMS to Advance Small Molecule Drug Discovery Programs

Shots:

  • CHARM will receive up front & is eligible to receive additional fees if BMS exercises its option to any of the program compounds. Additionally, both companies collaborated to identify & optimize compounds against selected targets
  • CHARM is in charge of the early discovery of drugs against targets of interest to BMS which has the option to license and develop drugs as a result of the partnership
  • The collaboration focuses to discover novel compounds against targets using CHARM’s DragonFold deep learning platform. The platform is designed to identify novel molecules through protein-ligand co-folding

Ref: CHARM Therapeutics | Image: CHARM Therapeutics

Related News:- BMS’ Reblozyl (luspatercept) Receives EC’s Approval for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions